GW Pharmaceuticals Buy Hold or Sell Recommendation

GWPRF -- USA Stock  

USD 13.92  0.40  2.76%

Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding GW Pharmaceuticals plc is 'Sell'. Macroaxis provides GW Pharmaceuticals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding GWPRF positions. The advice algorithm takes into account all of GW Pharmaceuticals plc available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from GWPRF buy-and-hold prospective. Please also check GW Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Execute Advice
Sell GW PharmaceuticalsBuy GW Pharmaceuticals


Hype Condition

Current Valuation

Odds of Distress

Analyst Consensus

Not Available
For the selected time horizon GW Pharmaceuticals plc has a mean deviation of 1.99, semi deviation of 0.0, standard deviation of 2.67, variance of 7.1, downside variance of 0.0 and semi variance of 0.0
Our buy or sell recommendation tool can be used to cross verify current analyst consensus on GW Pharmaceuticals plc and to analyze the organization potential to grow this quarter and beyond. To make sure GW Pharmaceuticals plc is not overpriced, please check out all GW Pharmaceuticals plc fundamentals including its Cash per Share, Total Asset and the relationship between Revenue and Cash Flow from Operations . Given that GW Pharmaceuticals plc has Price to Earning of (18.36)X, we strongly advise you confirm GW Pharmaceuticals market performance and probability of bankruptcy to make sure the company can sustain itself this quarter and beyond given your latest risk tolerance and investing horizon.

GW Pharmaceuticals Trading Alerts and Improvement Suggestions

GW Pharmaceuticals generates negative expected return over the last 30 days
The company reported revenue of 62.82M. Net Loss for the year was (268.23M) with loss before overhead, payroll, taxes, and interest of (19.8M).
GW PHARMACEUTICAL has accumulated about 521.67M in cash with (290.82M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.98 which can makes it an attractive takeover target, given it will continue generating positive cash flow.

GW Pharmaceuticals Returns Distribution Density

Mean Return0.1Value At Risk4.44
Potential Upside4.43Standard Deviation2.67
 Return Density 

GW Pharmaceuticals Greeks

Alpha over DOW
Beta against DOW=0.09
Overall volatility
Information ratio =0.1

GW Pharmaceuticals Volatility Alert

GW Pharmaceuticals plc exhibits very low volatility with skewness of -0.15 and kurtosis of -0.13. However, we advise investors to further study GW Pharmaceuticals plc technical indicators to make sure all market info is available and is reliable.
 Better Than Average     
 Worse Than Average Compare GW Pharmaceuticals to competition

GW Pharmaceuticals Fundamental Vs Peers

FundamentalsGW PharmaceuticalsPeer Average
Return On Equity(48.55)% (0.31)%
Return On Asset(26.90)% (0.14)%
Operating Margin(440.09)% (5.51)%
Current Valuation(35.49M)16.62B
Shares Outstanding368.62M571.82M
Shares Owned by Insiders2.75% 10.09%
Shares Owned by Institutions21.92% 39.21%
Price to Earning(18.36)X28.72X
Price to Book0.70X9.51X
Price to Sales85.67X11.42X
Gross Profit(19.8M)27.38B
Net Income(268.23M)570.98M
Cash and Equivalents521.67M2.7B
Cash per Share16.98X5.01X
Total Debt37.13M5.32B
Debt to Equity5.80% 48.70%
Current Ratio7.81X2.16X
Book Value Per Share20.83X1.93K
Cash Flow from Operations(290.82M)971.22M
Earnings Per Share(8.61)X3.12X
Number of Employees79118.84K
Market Capitalization5.38B19.03B
Total Asset453M29.47B
Retained Earnings(178M)9.33B
Working Capital370M1.48B
Current Asset405M9.34B
Current Liabilities35M7.9B
Z Score86.48.72

GW Pharmaceuticals Market Momentum